162 related articles for article (PubMed ID: 36906669)
1. Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms.
Gotfredsen K; Liisborg C; Skov V; Kjær L; Hasselbalch HC; Sørensen TL
Sci Rep; 2023 Mar; 13(1):4077. PubMed ID: 36906669
[TBL] [Abstract][Full Text] [Related]
2. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
Liisborg C
Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
[TBL] [Abstract][Full Text] [Related]
3. Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers.
Liisborg C; Skov V; Kjær L; Hasselbalch HC; Lykke Sørensen T
PLoS One; 2022; 17(6):e0269960. PubMed ID: 35709177
[TBL] [Abstract][Full Text] [Related]
4. Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation.
Liisborg C; Skov V; Kjær L; Hasselbalch HC; Sørensen TL
EClinicalMedicine; 2022 Jan; 43():101248. PubMed ID: 35128362
[TBL] [Abstract][Full Text] [Related]
5. Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system.
Liisborg C; Skov V; Kjær L; Hasselbalch HC; Sørensen TL
Aging (Albany NY); 2021 Dec; 13(24):25763-25777. PubMed ID: 34954692
[TBL] [Abstract][Full Text] [Related]
6. Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration.
Liisborg C; Nielsen MK; Hasselbalch HC; Sørensen TL
EClinicalMedicine; 2020 Sep; 26():100526. PubMed ID: 33089124
[TBL] [Abstract][Full Text] [Related]
7. Progression from intermediate to neovascular age-related macular degeneration according to drusen subtypes: Bundang AMD cohort study report 3.
Kim KL; Joo K; Park SJ; Park KH; Woo SJ
Acta Ophthalmol; 2022 May; 100(3):e710-e718. PubMed ID: 34390191
[TBL] [Abstract][Full Text] [Related]
8. Visual outcomes following cataract surgery in age-related macular degeneration patients.
Chen AX; Haueisen A; Rasendran C; Hom GL; Conti TF; Conti FF; Greenlee TE; Briskin IN; Bena JF; Singh RP; Talcott KE
Can J Ophthalmol; 2021 Dec; 56(6):348-354. PubMed ID: 33609442
[TBL] [Abstract][Full Text] [Related]
9. Neovascularization in Fellow Eye of Unilateral Neovascular Age-related Macular Degeneration According to Different Drusen Types.
Lee J; Choi S; Lee CS; Kim M; Kim SS; Koh HJ; Lee SC; Byeon SH
Am J Ophthalmol; 2019 Dec; 208():103-110. PubMed ID: 31377285
[TBL] [Abstract][Full Text] [Related]
10. Association between Patient-Reported Outcomes and Time to Late Age-Related Macular Degeneration in the Laser Intervention in Early Stages of Age-Related Macular Degeneration Study.
McGuinness MB; Finger RP; Wu Z; Luu CD; Chen FK; Arnold JJ; Chakravarthy U; Guymer RH;
Ophthalmol Retina; 2020 Sep; 4(9):881-888. PubMed ID: 32418845
[TBL] [Abstract][Full Text] [Related]
11. A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration.
Heloterä H; Kaarniranta K
Cells; 2022 Nov; 11(21):. PubMed ID: 36359849
[TBL] [Abstract][Full Text] [Related]
12. The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD.
Khan AH; Pierce CO; De Salvo G; Griffiths H; Nelson M; Cree AJ; Menon G; Lotery AJ
Eye (Lond); 2022 Nov; 36(11):2192-2199. PubMed ID: 34750590
[TBL] [Abstract][Full Text] [Related]
13. Drusen ooze: Predictor for progression of dry age-related macular degeneration.
Jhingan M; Singh SR; Samanta A; Arora S; Tucci D; Amarasekera S; Cagini C; Lupidi M; Chhablani J
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2687-2694. PubMed ID: 33710471
[TBL] [Abstract][Full Text] [Related]
14. Unravelling the therapeutic potential of IL-33 for atrophic AMD.
Clare AJ; Liu J; Copland DA; Theodoropoulou S; Dick AD
Eye (Lond); 2022 Feb; 36(2):266-272. PubMed ID: 34531552
[TBL] [Abstract][Full Text] [Related]
15. Imaging, Genetic, and Demographic Factors Associated With Conversion to Neovascular Age-Related Macular Degeneration: Secondary Analysis of a Randomized Clinical Trial.
Hallak JA; de Sisternes L; Osborne A; Yaspan B; Rubin DL; Leng T
JAMA Ophthalmol; 2019 Jul; 137(7):738-744. PubMed ID: 31021381
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 Plasma Levels Stratified by Sex in Intermediate Age-Related Macular Degeneration and Geographic Atrophy.
Rajeswaren V; Wagner BD; Patnaik JL; Mandava N; Mathias MT; Manoharan N; De Carlo Forest TE; Gnanaraj R; Lynch AM; Palestine AG;
Transl Vis Sci Technol; 2023 Aug; 12(8):1. PubMed ID: 37526620
[TBL] [Abstract][Full Text] [Related]
17. Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration.
Ahmed D; Stattin M; Haas AM; Graf A; Krepler K; Ansari-Shahrezaei S
BMC Ophthalmol; 2020 Sep; 20(1):381. PubMed ID: 32977799
[TBL] [Abstract][Full Text] [Related]
18. Bruch's Membrane and the Choroid in Age-Related Macular Degeneration.
Edwards M; Lutty GA
Adv Exp Med Biol; 2021; 1256():89-119. PubMed ID: 33847999
[TBL] [Abstract][Full Text] [Related]
19. Highly Expressed Amyloid Beta-42 Of Aqueous Humor In Patients With Neovascular Macular Degeneration.
Zhu J; Su T; Wang M; Li M; Liu L; Wang F
Semin Ophthalmol; 2021 Feb; 36(1-2):9-13. PubMed ID: 33587673
[No Abstract] [Full Text] [Related]
20. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
